| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | — | JP Morgan | Reinstates | → Underweight | |
| 08/29/2023 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/31/2023 | 1016.75% | Benchmark | → $22 | Reiterates | Buy → Buy |
| 05/19/2023 | 1016.75% | Benchmark | → $22 | Reiterates | Buy → Buy |
| 04/10/2023 | 1016.75% | Benchmark | → $22 | Upgrades | Hold → Buy |
| 03/17/2023 | 356.85% | JP Morgan | $23 → $9 | Downgrades | Neutral → Underweight |
| 11/10/2022 | — | Benchmark | Downgrades | Buy → Hold | |
| 11/09/2022 | 2691.88% | Chardan Capital | $65 → $55 | Maintains | Buy |
| 09/12/2022 | 1372.08% | Cowen & Co. | $30 → $29 | Maintains | Market Perform |
| 05/04/2022 | 1828.93% | Wells Fargo | $46 → $38 | Maintains | Equal-Weight |
| 04/29/2022 | 3199.49% | Chardan Capital | $75 → $65 | Maintains | Buy |
| 03/10/2022 | 1930.46% | Wells Fargo | $37 → $40 | Maintains | Equal-Weight |
| 11/10/2021 | 3707.11% | Chardan Capital | $92 → $75 | Maintains | Buy |
| 11/08/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/05/2021 | — | Argus Research | Downgrades | Buy → Hold | |
| 04/30/2021 | 4570.05% | Chardan Capital | $112 → $92 | Maintains | Buy |
| 04/07/2021 | 7514.21% | Benchmark | → $150 | Initiates Coverage On | → Buy |
| 02/24/2021 | 5585.28% | Chardan Capital | → $112 | Upgrades | Neutral → Buy |
| 02/19/2021 | 5585.28% | Chardan Capital | → $112 | Downgrades | Buy → Neutral |
| 01/08/2021 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 07/31/2020 | 5585.28% | Chardan Capital | $86 → $112 | Maintains | Buy |
| 07/17/2020 | 5483.76% | Cantor Fitzgerald | $85 → $110 | Maintains | Overweight |
| 06/08/2020 | 4214.72% | Cantor Fitzgerald | $86 → $85 | Maintains | Overweight |
| 05/06/2020 | 4468.53% | Argus Research | $67 → $90 | Maintains | Buy |
| 05/01/2020 | 4265.48% | Cantor Fitzgerald | $75 → $86 | Maintains | Overweight |
| 05/01/2020 | 4265.48% | Chardan Capital | $71 → $86 | Maintains | Buy |
| 04/30/2020 | 4214.72% | Wells Fargo | $75 → $85 | Maintains | Overweight |
| 02/25/2020 | 3707.11% | Wells Fargo | $66 → $75 | Maintains | Overweight |
| 09/12/2019 | 3199.49% | Guggenheim | → $65 | Initiates Coverage On | → Buy |
| 09/04/2019 | 3148.73% | Wells Fargo | $61 → $64 | Upgrades | Market Perform → Outperform |
What is the target price for Emergent BioSolutions (EBS)?
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by JP Morgan on November 20, 2023. The analyst firm set a price target for $0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Emergent BioSolutions (EBS)?
The latest analyst rating for Emergent BioSolutions (NYSE: EBS) was provided by JP Morgan, and Emergent BioSolutions their underweight rating.
When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Emergent BioSolutions (EBS) correct?
While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a with a price target of $0.00 to $0.00. The current price Emergent BioSolutions (EBS) is trading at is $1.97, which is out of the analyst's predicted range.